Grifols (GRFS) Projected to Post Earnings on Monday

Grifols (NASDAQ:GRFS - Get Free Report) is expected to be releasing its Q1 2025 earnings data on Monday, May 12th. Analysts expect Grifols to post earnings of $0.16 per share and revenue of $1.72 billion for the quarter.

Grifols Trading Up 1.4 %

Shares of NASDAQ:GRFS traded up $0.10 during midday trading on Wednesday, hitting $7.32. The company had a trading volume of 458,991 shares, compared to its average volume of 1,182,707. The firm has a fifty day simple moving average of $7.39 and a 200 day simple moving average of $7.68. The stock has a market cap of $5.03 billion, a price-to-earnings ratio of 6.26 and a beta of 0.44. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. Grifols has a 12 month low of $5.79 and a 12 month high of $9.96.

Analysts Set New Price Targets

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.